RTP Mobile Logo
Recent Developments in Clinical and Translational Research in NHL and CLL
Released August 2011

Roundtable participants include Drs Bruce D Cheson, Francine Foss, Jonathan W Friedberg, Steven M Horwitz, Brad S Kahl, John P Leonard, Peter McLaughlin and Andrew D Zelenetz. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Non-Hodgkin lymphoma (NHL) comprises a heterogeneous group of lymphoproliferative disorders and is one of the most rapidly evolving fields in hematology and oncology. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and changes in the use of existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. This program uses a roundtable discussion with leading clinical investigators to assist practicing clinicians in formulating up-to-date clinical management strategies for NHL and chronic lymphocytic leukemia (CLL).

    LEARNING OBJECTIVES
    • Develop an algorithm for the evaluation and treatment of newly diagnosed and relapsed/refractory CLL.
    • Communicate the existing and emerging roles of proteasome inhibitors and IMiDs for patients with mantle-cell lymphoma.
    • Integrate recent trial results with novel agents and regimens into the initial management of follicular lymphoma (FL).
    • Counsel patients with responding FL about the risks and benefits associated with consolidation and/or maintenance therapy.
    • Incorporate the results of recent research on the use of CNS prophylaxis into the management of diffuse large B-cell lymphoma.
    • Apply emerging research results to develop evidence-based clinical management strategies for newly diagnosed or recurrent T-cell lymphomas.
    • Counsel appropriately selected patients with lymphoid tumors about the availability of ongoing clinical trials in which they may be eligible to participate.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr ChesonAdvisory Committee: Allos Therapeutics, Celgene Corporation, Cephalon Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Millennium: The Takeda Oncology Company. Dr FossAdvisory Committee: Allos Therapeutics; Speakers Bureau: Allos Therapeutics, Celgene Corporation, Eisai Inc. Dr FriedbergAdvisory Committee: Cephalon Inc, Genentech BioOncology; Consulting Agreements: Mundipharma International Limited; Data and Safety Monitoring Board: Lilly USA LLC; Paid Research: Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc. Dr HorwitzConsulting Agreements: Allos Therapeutics, Celgene Corporation, Millennium: The Takeda Oncology Company; Paid Research: Allos Therapeutics, Genzyme Corporation. Dr KahlAdvisory Committee: Celgene Corporation, Cephalon Inc, Genentech BioOncology; Consulting Agreements: Celgene Corporation, Roche Laboratories Inc. Dr LeonardConsulting Agreements: Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi. Dr McLaughlinAdvisory Committee: Celgene Corporation, Genentech BioOncology, Seattle Genetics; Speakers Bureau: Spectrum Pharmaceuticals Inc. Dr ZelenetzConsulting Agreements: Celgene Corporation, Cell Therapeutics Inc, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline; Paid Research: Amgen Inc, Genentech BioOncology, GlaxoSmithKline.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company and Sanofi.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012

Acknowledge and close

Listen to Audio:
Recent Developments in Clinical and Translational Research in NHL and CLL
Released August 2011

Roundtable participants include Drs Bruce D Cheson, Francine Foss, Jonathan W Friedberg, Steven M Horwitz, Brad S Kahl, John P Leonard, Peter McLaughlin and Andrew D Zelenetz. (Text and Audio Content)

Read print: